Trial Profile
A Randomised, Double Blind Study Comparing Fixed Doses of 0.25mg, 0.5mg and 0.75mg Pramipexole to Investigate the Efficacy and Safety in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by 46 Weeks Open Label Long Term Study to Investigate the Safety and Efficacy of Pramipexole
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 08 Aug 2009 Status changed from active, no longer recruiting to completed.
- 11 Jun 2009 Results preseneted at the 13th International Congress of Parkinson's Disease and Movement Disorders
- 11 Jun 2009 Status change from active, no longer recruiting to completed